Bezafibrate
- Atc Codes:C10AB02
- CAS Codes:41859-67-0
- PHARMGKB ID:41859-67-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Bezafibrat, Bezalip, Bezastad; Belgium: Cedur, Eulitop; Cyprus: Lacromid; Czech Republic: Bezalip, Bezamidin, Regadrin; Denmark: Bezafibrat; Finland: Bezalip; France: Befizal; Germany: Befibrat, Bezafibrat, Bezagamma, Cedur, Lipox Bezafibrat Retardtabletten; Greece: Bezalip; Hungary: Bezalip; Ireland: Bezalip; Italy: Bezalip; Luxembourg: Bezacur, Cedur; Netherlands: Bezalip; Poland: Bezalip, Bezamidin; Portugal: Bezalip; Romania: Bezafibrat, Regadrin; Slovenia: Etifibrat; Spain: Difaterol, Eulitop; Sweden: Bezalip; UK: Bezalip.
North America
Canada: Bezalip, Bezafibrate.
Latin America
Argentina: Bezacur, Bezalip, Elpi Lip; Brazil: Bezafibrato, Cedur; Mexico: Befitec, Bexalcor, Bezafibrato, Bezafisal, Bezalex, Bifarén, Bionolip, Colser, Fazebit, Lesbest, Lipocín, Neptalip, Nivetril, Redalip, Safital, Saprame, Zaf.
Asia
Japan: Anibesol, Befarlart, Beriatol, Besastar, Betlol, Bezafibrate, Bezalex, Bezalip, Bezasafe, Bezatate, Bezaterio, Bezatol, Bunatol, Busyarlu, Kenperate, Midenal, Modobil, Natoris, Vesturit.
Drug combinations
Chemistry
Bezafibrate: C~19~H~20~ClNO~4~. Mw: 361.82. (1) Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-; (2) 2-[p-[2-(p-Chlorobenzamido)ethyl]phenoxy]-2-methylpropionic acid. CAS-41859-67-0 (1978).
Pharmacologic Category
Antilipemic Agents; Fibric Acid Derivatives. (ATC-Code: C10AB02).
Mechanism of action
Mechanism not established. May increase VLDL catabolism by increasing lipoprotein and hepatic triglyceride lipase activities. May decrease triglyceride biosynthesis by inhibition of acetyl-CoA carboxylase. May decrease cholesterol biosynthesis by inhibition of 3-hydroxy-3-methyglutaryl-coenzyme A reductase.
Therapeutic use
Adjunct to diet and other therapeutic measures for treatment of type II~a~ and II~b~ mixed hyperlipidemia, to regulate lipid and apoprotein levels (reduce serum triglycerides, LDL-C and apolipoprotein B, increase HDL-C and apolipoprotein A). Treatment of adult patients with high to very high triglyceride levels (hypertriglyceridemia)(Fredrickson classification type IV and V hyperlipidemias) who are at high risk of complications from their dyslipidemia.
Pregnancy and lactiation implications
Embryotoxicity reported in animals. Women planning pregnancy should discontinue bezafibrate several months before conception. Contraindicated during lactation.
Unlabeled use
Contraindications
Hypersensitivity to bezafibrate, fibrates, or any component of the formulation. Hepatic or renal dysfunction. Primary biliary cirrhosis. Pre-existing gallbladder disease. Concurrent use of MAO inhibitors. Pregnancy or breast-feeding. Not indicated for the treatment of type I hyperlipoproteinemia.
Warnings and precautions
Hepatotoxic (caution in history of jaundice or hepatic disorder). Has been associated with rare myositis or rhabdomyolysis. Possibly tumorigenic in animals. Caution in renal impairment, hypoalbuminemia, or nephrotic syndrome. Caution with HMG-CoA reductase inhibitors (may lead to myopathy, rhabdomyolysis). Caution with warfarin.